There are no items in your cart
Add More
Add More
| Item Details | Price | ||
|---|---|---|---|
Launch your Graphy
100K+ creators trust Graphy to teach online
Earnings Snapshot · Simple Trade With Patience
Five results from today's earnings day, side by side — a mix of beats, a miss, and one that fell despite a headline profit jump. Tap a name to open its snapshot.
Up from ₹659.2cr in Q1 FY26. Revenue jumped 25.2% to ₹6,378cr, with EBITDA margin expanding to 24.1% from 21.6% — a broad-based beat that comfortably topped Street estimates of ₹730–830cr.
All four product groups delivered double-digit growth. This is a clear beat vs Street — even the most bullish pre-results estimate (+34% YoY PAT) undershot the actual +48%. Stock hit a fresh high, up 3–4% on the day.
Up sharply from ₹604cr in Q1 FY26. Asset quality improved — GNPA down to 3.25% from 3.43% QoQ — even as advances shrank slightly and provisions eased.
Sequentially, standalone profit rose 88% QoQ (₹1,002.5cr vs ₹532.7cr in Q4 FY26) — a bank still working through a rough patch, but Q1 FY27 shows a clear turn: lower provisions, improving asset quality, and a low base from last year all working in its favour.
Up from ₹824cr in Q1 FY26. Revenue growth (+11.9%) lagged profit growth as EBITDA margin expanded to 90% from 80% — a leaner, more efficient quarter even as the stock slipped on profit booking.
Profit growth was solid but revenue growth was the slowest of this batch at just 11.9% YoY — margin expansion, not top-line momentum, did the heavy lifting. The stock fell despite the beat, suggesting the market wanted more from the growth line, not just the bottom line.
Down sharply from ₹1,417.8cr in Q1 FY26. Revenue also declined 5.6%, dragged by a 35% fall in North America sales and a one-off inventory provision tied to semaglutide API.
A clear miss — both revenue and profit down, margins compressed by roughly 3 percentage points from a ₹239.7cr semaglutide-API inventory provision. The North America decline (-35%) is the number to watch into next quarter.
Record quarterly performance for the chemicals-to-technical-textiles conglomerate. Revenue grew 32% YoY, with the Board also approving a ₹5/share interim dividend and fresh capex.
Company itself is calling this a "record performance" — profit growth (+76%) comfortably outpacing revenue growth (+32%) points to strong operating leverage and margin recovery in the Chemicals segment after a period of Chinese pricing pressure.
Launch your Graphy